Omega Therapeutics, Inc.
OMGA
Price:
$0.786
Market Cap:
$43.52M
Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regenera...[Read more]
Industry
Biotechnology
IPO Date
2021-07-30
Stock Exchange
NASDAQ
Ticker
OMGA
PE Ratio
[-0.60]
ROE
[-213.14%]
Current Ratio
[1.61]
Dividend Yield
[0%]
Enterprise Value
[141.27M]
Dividend History
The ROE as of November 2024 (TTM) for Omega Therapeutics, Inc. (OMGA) is -213.14%
According to Omega Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -213.14%. This represents a change of 195.96% compared to the average of -72.02% of the last 4 quarters.
Omega Therapeutics, Inc. (OMGA) Historical ROE (quarterly & annually)
How has OMGA ROE performed in the past?
The mean historical ROE of Omega Therapeutics, Inc. over the last ten years is -40.19%. The current -213.14% ROE has changed 430.33% with respect to the historical average. Over the past ten years (40 quarters), OMGA's ROE was at its highest in in the March 2020 quarter at 58.82%. The ROE was at its lowest in in the September 2024 quarter at -142.46%.
Average
-40.19%
Median
-34.47%
Minimum
-167.93%
Maximum
51.59%
Omega Therapeutics, Inc. (OMGA) ROE by Quarter and Year
Discovering the peaks and valleys of Omega Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 180.95%
Maximum Annual ROE = 51.59%
Minimum Annual Increase = -173.77%
Minimum Annual ROE = -167.93%
| Year | ROE | Change |
|---|---|---|
| 2023 | -167.93% | 73.39% |
| 2022 | -96.85% | 180.95% |
| 2021 | -34.47% | -173.77% |
| 2020 | 46.73% | -9.42% |
Omega Therapeutics, Inc. (OMGA) Average ROE
How has OMGA ROE performed in the past?
The current ROE of Omega Therapeutics, Inc. (OMGA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-99.75%
5-year avg
-40.19%
10-year avg
-40.19%
Omega Therapeutics, Inc. (OMGA) ROE vs. Peers
How is OMGA’s ROE compared to its peers?
Omega Therapeutics, Inc.’s ROE is greater than PMV Pharmaceuticals, Inc. (-24.20%), greater than Eliem Therapeutics, Inc. (-47.03%), greater than MediciNova, Inc. (-20.70%), greater than Pharvaris N.V. (-38.27%), greater than PepGen Inc. (-60.17%), greater than Olema Pharmaceuticals, Inc. (-53.55%), greater than Nuvectis Pharma, Inc. (-155.80%), greater than Larimar Therapeutics, Inc. (-35.87%), greater than Centessa Pharmaceuticals plc (-52.22%), greater than Orchestra BioMed Holdings, Inc. (-107.04%), greater than Aerovate Therapeutics, Inc. (-90.19%), greater than Enliven Therapeutics, Inc. (-29.46%), greater than MoonLake Immunotherapeutics (-15.89%), greater than Structure Therapeutics Inc. (-16.40%), greater than Compass Therapeutics, Inc. (-28.67%), greater than Mineralys Therapeutics, Inc. (-55.92%), greater than Cadrenal Therapeutics, Inc. Common Stock (-142.95%),
| Company | ROE | Market cap |
|---|---|---|
| -24.20% | $83.31M | |
| -47.03% | $342.68M | |
| -20.70% | $104.47M | |
| -38.27% | $1.20B | |
| -60.17% | $143.75M | |
| -53.55% | $503.07M | |
| -155.80% | $98.54M | |
| -35.87% | $393.05M | |
| -52.22% | $2.06B | |
| -107.04% | $219.34M | |
| -90.19% | $76.81M | |
| -29.46% | $1.20B | |
| -15.89% | $3.43B | |
| -16.40% | $1.91B | |
| -28.67% | $205.01M | |
| -55.92% | $621.09M | |
| -142.95% | $24.86M |
Build a custom stock screener for Omega Therapeutics, Inc. (OMGA) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Omega Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Omega Therapeutics, Inc. (OMGA) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Omega Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Omega Therapeutics, Inc.'s ROE?
How is the ROE calculated for Omega Therapeutics, Inc. (OMGA)?
What is the highest ROE for Omega Therapeutics, Inc. (OMGA)?
What is the 3-year average ROE for Omega Therapeutics, Inc. (OMGA)?
What is the 5-year average ROE for Omega Therapeutics, Inc. (OMGA)?
How does the current ROE for Omega Therapeutics, Inc. (OMGA) compare to its historical average?